Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30291858 | 1.00 | AR (1.00) | ARHDAC1 | |
| SCHEMBL4031610 | 0.89 | AR (0.80) | ARHDAC1 | |
| SCHEMBL7035063 | 0.88 | AR (0.87) | ARHDAC1 | |
| SCHEMBL4026199 | 0.88 | AR (0.78) | AR | |
| SCHEMBL8939558 | 0.87 | AR (0.77) | ARHDAC1 | |
| SCHEMBL4024954 | 0.86 | AR (0.76) | ARHDAC1 | |
| SCHEMBL4023040 | 0.86 | AR (0.75) | ARHDAC1 | |
| SCHEMBL4024956 | 0.85 | AR (0.77) | ARHDAC1 | |
| SCHEMBL8704637 | 0.85 | AR (0.77) | ARHDAC1 | |
| SCHEMBL4023027 | 0.85 | AR (0.74) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE35956-E | Phenylimidazolidines having antiandrogenic activity | ROUSSEL UCLAF (FR) | 1998-11-10 | — | — | US | claimed |
| US-5627201-A | Phenylimidazolidines having antiandrogenic activity | ROUSSEL UCLAF (FR) | 1997-05-06 | — | — | US | claimed |
| EP-0494819-B1 | Phenylimidazolidines, their process for fabrication, their application as medicaments and the pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1996-07-10 | — | — | EP | claimed |
| US-5411981-A | Phenylimidazolidines having antiandrogenic activity | ROUSSEL UCLAF (FR) | 1995-05-02 | — | — | US | claimed |
| EP-0494819-A1 | Phenylimidazolidines, their process for fabrication, their application as medicaments and the pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1992-07-15 | — | — | EP | claimed |
| WO-2023275091-A1 | PROCESSES FOR THE PREPARATION OF NON-STEROIDAL ANTIANDROGENS | Química Sintética, S.A. (ES) | 2023-01-05 | — | — | WO | disclosed |
| EP-4112603-A1 | PROCESSES FOR THE PREPARATION OF NON-STEROIDAL ANTIANDROGENS | Química Sintética, S.A. (ES) | 2023-01-04 | — | — | EP | disclosed |
| EP-3725778-B1 | FORMULATIONS OF ENZALUTAMIDE | MEDIVATION PROSTATE THERAPEUTICS LLC (US) | 2021-08-18 | — | — | EP | disclosed |
| US-20210040044-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. | 2021-02-11 | — | — | US | disclosed |
| US-10844021-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| EP-3660004-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas Operations, Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| WO-2020042622-A1 | COMPOUND, COMPOSITION, AND USE THEREOF IN PREPARATION OF DRUG | 长沙泽达医药科技有限公司 | 2020-03-05 | — | — | WO | disclosed |
| EP-0671156-B1 | Process to prepare cosmetic or pharmaceutical compositions containing liposomes | AVENTIS PHARMA SA (FR) | 2001-10-24 | — | — | EP | disclosed |
| US-6162444-A | Cosmetic or pharmaceutical compositions | HOECHST MARION ROUSSEL (FR) | 2000-12-19 | — | — | US | disclosed |
| US-RE35956-E | Phenylimidazolidines having antiandrogenic activity | ROUSSEL UCLAF (FR) | 1998-11-10 | — | — | US | disclosed |
| US-5627201-A | Phenylimidazolidines having antiandrogenic activity | ROUSSEL UCLAF (FR) | 1997-05-06 | — | — | US | disclosed |
| EP-0494819-B1 | Phenylimidazolidines, their process for fabrication, their application as medicaments and the pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1996-07-10 | — | — | EP | disclosed |
| EP-0671156-A1 | Cosmetic or pharmaceutical compositions containing liposomes | ROUSSEL UCLAF (FR) | 1995-09-13 | — | — | EP | disclosed |
| US-5411981-A | Phenylimidazolidines having antiandrogenic activity | ROUSSEL UCLAF (FR) | 1995-05-02 | — | — | US | disclosed |
| EP-0494819-A1 | Phenylimidazolidines, their process for fabrication, their application as medicaments and the pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1992-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040044-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | AR 1/4885HDAC1 1306/4885 |
| US-10844021-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | AR 1/4885HDAC1 1306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.